Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.84 HKD | +4.67% | -.--% | +35.54% |
May. 24 | Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation | MT |
May. 24 | Henlius' EU Marketing Application for Denosumab Biosimilar Accepted and Validated by Regulator | MT |
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+35.54% | 1.31B | - | ||
-2.29% | 89.87B | A- | ||
-3.95% | 37.57B | A- | ||
-13.07% | 32.75B | B- | ||
+63.05% | 26.47B | A | ||
-22.14% | 14.25B | C | ||
-7.96% | 12.99B | B- | ||
-9.33% | 11.93B | D+ | ||
-46.33% | 10.84B | B | ||
+5.77% | 9.11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2696 Stock
- Ratings Shanghai Henlius Biotech, Inc.